Skip to main content
Journal cover image

Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?

Publication ,  Journal Article
Ambrosy, AP; Fudim, M; Chioncel, O
Published in: Eur J Heart Fail
November 2019

Duke Scholars

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

November 2019

Volume

21

Issue

11

Start / End Page

1398 / 1401

Location

England

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Humans
  • Heart Failure
  • Drug Combinations
  • Cardiovascular System & Hematology
  • Biphenyl Compounds
  • Aminobutyrates
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ambrosy, A. P., Fudim, M., & Chioncel, O. (2019). Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations? Eur J Heart Fail, 21(11), 1398–1401. https://doi.org/10.1002/ejhf.1555
Ambrosy, Andrew P., Marat Fudim, and Ovidiu Chioncel. “Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?Eur J Heart Fail 21, no. 11 (November 2019): 1398–1401. https://doi.org/10.1002/ejhf.1555.
Ambrosy, Andrew P., et al. “Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?Eur J Heart Fail, vol. 21, no. 11, Nov. 2019, pp. 1398–401. Pubmed, doi:10.1002/ejhf.1555.
Journal cover image

Published In

Eur J Heart Fail

DOI

EISSN

1879-0844

Publication Date

November 2019

Volume

21

Issue

11

Start / End Page

1398 / 1401

Location

England

Related Subject Headings

  • Valsartan
  • Tetrazoles
  • Humans
  • Heart Failure
  • Drug Combinations
  • Cardiovascular System & Hematology
  • Biphenyl Compounds
  • Aminobutyrates
  • 3201 Cardiovascular medicine and haematology
  • 1102 Cardiorespiratory Medicine and Haematology